New Antimicrobial Class; Loloatins

13 October 1996

- A new family of antibiotics isolated from a marine organism may be of use in treating infections which are resistant to multiple drugs. The class, called loloatins, were isolated from a marine microbe collected on the Great Barrier Reef by Canadian company SeaTek Marine. The loloatins comprise a family of three 10-amino-acid proteins in a ring structure, which exhibit activity at low concentrations against antibiotic-resistant Staphylococcus aureus, Enterococcus faecium, Streptococcus pneumoniae and others.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight